We speak to Matthew Dunne, Director for Drug Discovery at Micreos Pharmaceuticals, about the importance of creating new targeted antibacterial products.
Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace
/PRNewswire/ Micreos Pharmaceuticals today announces findings from a study proving the effectiveness of XZ.700, a novel antibacterial enzyme, in selectively.